US Bancorp DE Sells 651 Shares of Cencora, Inc. (NYSE:COR)

US Bancorp DE lessened its position in shares of Cencora, Inc. (NYSE:COR) by 1.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,356 shares of the company’s stock after selling 651 shares during the quarter. US Bancorp DE’s holdings in Cencora were worth $11,785,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. New Millennium Group LLC acquired a new position in shares of Cencora during the second quarter worth $26,000. TCTC Holdings LLC purchased a new position in Cencora during the 1st quarter worth $29,000. TFO Wealth Partners LLC acquired a new position in Cencora during the 1st quarter valued at about $30,000. MFA Wealth Advisors LLC purchased a new stake in Cencora in the second quarter valued at about $30,000. Finally, Concord Wealth Partners acquired a new stake in Cencora in the third quarter worth about $30,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Robert W. Baird cut their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a report on Friday, September 6th. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Wells Fargo & Company lifted their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. upped their target price on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Finally, Bank of America reiterated a “neutral” rating and set a $245.00 price target (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $259.44.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 15.80% of the stock is currently owned by insiders.

Cencora Stock Performance

Shares of COR stock opened at $234.27 on Friday. Cencora, Inc. has a 52-week low of $184.00 and a 52-week high of $247.66. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The stock has a market cap of $46.16 billion, a PE ratio of 25.44, a price-to-earnings-growth ratio of 1.46 and a beta of 0.44. The business has a 50-day simple moving average of $231.39 and a 200-day simple moving average of $230.65.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.18 by $0.16. The business had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.92 EPS. On average, equities analysts expect that Cencora, Inc. will post 13.64 EPS for the current year.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.